News | Cardiovascular Ultrasound | September 14, 2021

FDA Clears Fully Automated Cardiac Ultrasound Solution to Measure 2D and Doppler

The Us2.ai artificial intelligence received external validation at Brigham and Women's Hospital of Harvard Medical School

Us2.ai has received U.S. Food and Drug Administration (FDA) clearance for its artificial intelligence (AI) Us2.v1 software, a completely automated decision support tool for echocardiography.

September 14, 2021 – Us2.ai, a Singapore-based medtech firm backed by Sequoia India and EDBI, has received U.S. Food and Drug Administration (FDA) clearance for Us2.v1, a completely automated decision support tool for echocardiography.

After multiple trials with global pharmaceutical partners, and a validation study at the Brigham & Women’s Hospital, Us2.ai announced the artificial intelligence (AI) software is now available for clinical use in the United States. 

Us2.v1 is an automated clinical workflow solution that recognizes and analyzes 2-dimensional and Doppler echo images for comprehensive cardiac ultrasound measurements needed for the diagnosis, prediction and prognosis of heart disease.

"With this release, we’ve moved the field of AI beyond just a narrow feature for echocardiography, to a complete decision-support solution for cardiologists and primary care providers,” said James Hare, CEO and co-founder of Us2.ai. “Us2.v1 eliminates the manual workflows and lack of transparency from semi-automated, single measurement, black box AI approaches, creating a complete and fully automated patient report with editable annotations, conclusions and comparisons to international reference guidelines.”

Us2.v1 automated measurements include 2-D (cardiac volumes, all 4 chambers of the heart), M-mode (e.g. tricuspid annular plane systolic excursion), spectral Doppler (blood flow across all valves, both PW and CW measurements) and tissue Doppler; thus covering the vast majority of standard measurements for adult transthoracic echocardiography recommended by the American Society of Echocardiography (ASE), European Association of Cardiovascular Imaging, and British Society of Echocardiography.  

Fully automated Us2.v1 measurements were shown to be completely interchangeable with expert human measurements. The AI measurements also were completely reproducible for a given patient study, with image processing/analysis algorithm computation time of approximately 2 minutes per study, the vendor said.

Us2.v1 is designed to help to accelerate the diagnosis of diseases such as pulmonary hypertension and heart failure (HF). 

The company recently announced a partnership with EchoNous, maker of ultra-portable, AI-guided, point-of-care ultrasound (POCUS) tools. EchoNous is the maker of Kosmos, the only handheld ultra-mobile tool offering diagnostic grade imaging with Continuous-Wave (CW) Doppler capability.

Us2.v1 also automates the detection of pulmonary hypertension according to the European Society of Cardiology (ESC) / European Respiratory Society (ERS) guideline definition for echocardiographic detection of pulmonary hypertension. Pulmonary hypertension remains under-detected, leading to treatment delays and poor outcomes. 

Similarly, heart failure is a commonly missed diagnosis, particularly in general practices where access to echocardiography is currently limited. 

“AstraZeneca is excited to partner with Us2.ai because we believe it has the potential to transform the management of heart failure, bringing early access to echocardiography, including expert-level analyses, to primary care settings, the general community and even to patients’ home. Together, we look forward to helping improve care for patients with heart failure and keeping them out of hospital”, said Joris Silon, senior vice president, CVRM, bioPharmaceuticals business unit, AstraZeneca.

For more information: https://us2.ai/

Find more artificial intelligenece in cardiology content

Find more new cardiac ultrasound technology content

Related Content

An example of artificial intelligence on the GE Healthcare Vivid E95 system shown at ASE 2019 where the AI automatically pulls in an exam, identifies the left ventricle and myocardial boards and then calculates all the strain measurements in less than 10 seconds. While AI automation can greatly speed workflow, there are questions about the accuracy of AI for the next step in making diagnoses.  #ASE #ASE21 #ASE2021 #AI

An example of artificial intelligence on the GE Healthcare Vivid E95 system shown at ASE 2019 where the AI automatically pulls in an exam, identifies the left ventricle and myocardial boards and then calculates all the strain measurements in less than 10 seconds. While AI automation can greatly speed workflow, there are questions about the accuracy of AI for the next step in making diagnoses. 

Feature | Artificial Intelligence | September 08, 2021 | By Dave Fornell, Editor
Artificial intelligence is becoming best practice to support clinical decisions and help standardize echocardiography analysis for practices. AI, trained on millions of outcome-based data, can provide automation for operators to obtain highly accurate and precise measurements, to better detect and predict cardiovascular disease.
Webinar | Artificial Intelligence | August 12, 2021
Artificial intelligence is becoming best practice to support clinical decisions and help standardize echocardiography
An example of Viz.AI's pulmonary embolism AI application and mobile alert to the physician on-call. Viz.AI and Avicenna.AI Partner to Launch Artificial Intelligence Care Coordination for Pulmonary Embolism and Aortic Disease

An example of Viz.AI's pulmonary embolism AI application and mobile alert to the physician on-call.

News | Artificial Intelligence | July 21, 2021
July 21, 2021 — Artificial int...
Circle Cardiovascular Imaging Partners With DiA Imaging Analysis to Deliver AI-Based Cardiovascular Imaging Solutions
News | Artificial Intelligence | June 28, 2021
June 28, 2021 — Circle Cardiovascular Imaging Inc. and DiA Imaging Analysis Ltd.
Point of care ultrasound, POCUS, combined with artificial intelligence, can help improve echo image quality by inexperienced sonographers.

Getty Images

News | Artificial Intelligence | June 25, 2021
June 25, 2021 – COVID-19 changed everything in healthcare, and a benefit from this pandemic was a surge in innovation
GE is integrating artificial intelligence into most of its imaging and information technology software. AI can aid fast critical care decision making. Above left is the vScan Air wireless point-of-care ultrasound system. It integrates AI for immediate, automated assessment of a patient's ejection fraction, right.

GE is integrating artificial intelligence into most of its imaging and information technology software. AI can aid fast critical care decision making. Above left is the vScan Air wireless point-of-care ultrasound system. It integrates AI for immediate, automated assessment of a patient's ejection fraction, right.

Feature | Artificial Intelligence | June 10, 2021
The digital transformation of healthcare is underway, but it will advance further and faster if key stakeholders work
AI Med will present its Virtual Clinical Series: Imaging Built by Clinicians, for Clinicians, June 29-30, 2021.
News | Artificial Intelligence | June 09, 2021
June 9, 2021 — AI Med will present its...